Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !
Fique off-line com o app Player FM !
Intensity Therapeutics Doses First U.S. Patient in Phase 3 Study for Metastatic Sarcoma Treatment
MP3•Home de episódios
Manage episode 434198914 series 2891889
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Intensity Therapeutics CEO Lew Bender joined Steve Darling from Proactive to announce a significant milestone: the first U.S. patient has been dosed in the company's pivotal Phase 3 clinical trial for treating metastatic sarcoma. This global superiority study is designed to evaluate the efficacy of INT230-6, a novel therapeutic agent, as a monotherapy compared to the investigator's choice of three standard-of-care systemic chemotherapy drugs. The trial focuses on second or third-line treatment for patients with metastatic, recurrent, or inoperable soft tissue sarcomas (STS). Bender highlighted that the Phase 3 trial aims to enroll approximately 333 patients worldwide, with the primary endpoint being overall survival. The study is structured so that for every three patients enrolled, two will receive INT230-6, and one will receive the current standard of care. The trial specifically targets STS subtypes including leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. This Phase 3 study follows promising data from Intensity Therapeutics' earlier Phase 1/2 trial, where INT230-6 demonstrated significant tumor-killing and immune-activating properties, leading to increased survival rates in patients with metastatic disease. Soft tissue sarcoma is a rare and challenging type of cancer that originates in the body's soft tissues, such as muscles, fat, blood vessels, nerves, tendons, and the linings of joints. The disease most commonly affects the arms, legs, and abdomen. In the United States, approximately 197,000 patients are living with sarcoma, which encompasses more than 50 different subtypes. Initial treatment typically involves surgery, but the recurrence or metastasis of the disease often necessitates additional therapeutic approaches, underscoring the importance of new treatment options like INT230-6. #proactiveinvestors #intensitytherapeuticsinc #nasdaq #ints #CancerTreatment #IntensityTherapeutics #LewBender #Phase3Trial #Sarcoma #BreastCancer #InnovativeTherapy #Immunotherapy #Oncology #Biotech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episódios
MP3•Home de episódios
Manage episode 434198914 series 2891889
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Intensity Therapeutics CEO Lew Bender joined Steve Darling from Proactive to announce a significant milestone: the first U.S. patient has been dosed in the company's pivotal Phase 3 clinical trial for treating metastatic sarcoma. This global superiority study is designed to evaluate the efficacy of INT230-6, a novel therapeutic agent, as a monotherapy compared to the investigator's choice of three standard-of-care systemic chemotherapy drugs. The trial focuses on second or third-line treatment for patients with metastatic, recurrent, or inoperable soft tissue sarcomas (STS). Bender highlighted that the Phase 3 trial aims to enroll approximately 333 patients worldwide, with the primary endpoint being overall survival. The study is structured so that for every three patients enrolled, two will receive INT230-6, and one will receive the current standard of care. The trial specifically targets STS subtypes including leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma. This Phase 3 study follows promising data from Intensity Therapeutics' earlier Phase 1/2 trial, where INT230-6 demonstrated significant tumor-killing and immune-activating properties, leading to increased survival rates in patients with metastatic disease. Soft tissue sarcoma is a rare and challenging type of cancer that originates in the body's soft tissues, such as muscles, fat, blood vessels, nerves, tendons, and the linings of joints. The disease most commonly affects the arms, legs, and abdomen. In the United States, approximately 197,000 patients are living with sarcoma, which encompasses more than 50 different subtypes. Initial treatment typically involves surgery, but the recurrence or metastasis of the disease often necessitates additional therapeutic approaches, underscoring the importance of new treatment options like INT230-6. #proactiveinvestors #intensitytherapeuticsinc #nasdaq #ints #CancerTreatment #IntensityTherapeutics #LewBender #Phase3Trial #Sarcoma #BreastCancer #InnovativeTherapy #Immunotherapy #Oncology #Biotech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
607 episódios
सभी एपिसोड
×Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.